Outcome
Type |
Measure |
Description |
Time frame |
Safety issue |
Primary |
Brain maturation assessed by magnetic resonance imaging (MRI) |
MRI with spectroscopy (MRS) and diffusion tensor imaging (DTI) will be used to examine myelinisation and quantification of anatomical structures as well as neuronal integrity and inflammation |
40 weeks postmenstrual age (PMA) |
|
Secondary |
Weight gain |
Weight measurements, including weight nadir. |
Weight will be recorded until 36 weeks PMA and at 3, 6, 12 and 24 months and 8 years corrected age. |
|
Secondary |
Growth |
Length and head circumference (HC). |
Length and HC will be recorded until 36 weeks PMA and at 3, 6, 12 and 24 months and 8 years corrected age. |
|
Secondary |
Body composition |
Body composition will be assessed using PEA POD, an air displacement plethysmography system and Dexa Scan. |
At 36 weeks PMA, 3 months and 2 years corrected age |
|
Secondary |
Neonatal morbidities associated with inflammation |
Bronchopulmonary dysplasia (BPD), retinopathy of prematurity (ROP), necrotizing enterocolitis (NEC), white matter injury (WMI) of the brain, and late onset septicemia |
From birth til 36 weeks PMA |
|
Secondary |
Cerebral Background Activity evaluated by Electroencephalogram (EEG) |
EEG maturational changes will be examined as a function of time and as a function of gestational age |
First week of life, 36 weeks PMA and 2 years corrected age (CA) |
|
Secondary |
Neurodevelopment assessed by standardized motor and cognitive tests |
Evaluation of psychomotor development by performing Bayley III and a standardized neurological examination |
2 years corrected age (CA) |
|
Secondary |
Lung function evaluated by tidal breathing measurements |
Tidal breathing measurements include tidal volume, respiratory rate, minute ventilation and fraction of expiratory time to peak tidal expiratory flow to total expiratory time |
36 weeks PMA, 3 months and 2 years CA |
|
Secondary |
Cardiovascular Health assessed by echocardiography |
Echocardiography will be used to follow the transition from fetal to completed neonatal circulation, to measure superior vena cava flow, and to study mycardial function by the use of conventional two-dimensional echocardiography and tissue Doppler imaging. |
First week of life, 2nd week of life, at 36 weeks PMA and 2 years CA |
|
Secondary |
Blood pressure |
Measurements of systolic, diastolic and mean pressure |
First week of life and at 36 weeks PMA and 2 years CA |
|
Secondary |
Fatty acid (FA) profiles in blood |
Repeated dried blood spots (DBS) samples with approximately 10 µL blood will be collected for FA analyses. These analyses are important for assessing efficacy and protocol compliance. We will also collect 10 µL of fullblood for assessment of total lipid profile (Lipidomics). |
From birth until 36 weeks PMA |
|
Secondary |
Markers of inflammation |
Inflammation panels will be used to assess markers of inflammation in fullblood and sputum |
From birth until 36 weeks PMA |
|
Secondary |
Markers of metabolic status |
Metabolic pathway analyses (http://omictools.com/metabolic-pathways-category) will be performed to analyse and describe the metabolic conditions of the infants during hospitalization. Metabolites outside the standard clinical chemistry parameters will also be investigated ("untargeted metabolomics). Metabolomics will be performed by the use of dried blood spot samples |
From birth until 36 weeks PMA |
|
Secondary |
Markers of nutritional status in blood |
The concentrations of electrolytes, minerals, albumin, alkaline phosphatase, vitamin A and D will be assessed regularly during hospitalization |
From birth until 36 weeks PMA |
|
Secondary |
Micronutrient content in urine |
Spot urine will be obtained regularly to study the changes in electrolyte- and mineral homeostasis during the first week of life as well as during the phase of steady growth |
From birth until 36 weeks PMA |
|
Secondary |
Evaluation of nutrient composition of expressed breast milk |
Repeated samples of breast milk will be collected for FA analyses, macronutrient content and vitamin A |
From birth until 36 weeks PMA |
|
Secondary |
Gut microbiota |
Repeated samples of feces will be used to study the early fecal microbiota |
From birth until 36 weeks PMA |
|
Secondary |
Inflammatory markers in sputum |
We will analyze the Expression of a standardized panel of inflammatory markers in collected laryngeal or tracheal secretion |
From birth until 36 weeks PMA |
|